Chronic Refractory Cough Pipeline 2024 | GSK, Trevi Therapeutics

DelveInsight's, "Chronic Refractory Cough Pipeline Insight 2024" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chronic Refractory Cough pipeline landscape. It covers the Chronic Refractory Cough pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Refractory Cough therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chronic Refractory Cough Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Refractory Cough Pipeline Outlook [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Refractory Cough Pipeline Report

* July 2024:- Trevi Therapeutics - A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough. A 2-period crossover study for the treatment of cough in patients with Refractory Chronic Cough via Nalbuphine ER (NAL ER).
* July 2024:- Nocion Therapeutics- A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Taplucainium Inhalation Powder (NOC-110) in Adults With Refractory or Unexplained Chronic Cough. This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
* July 2024:- Genentech Inc.:- A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough. This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.
* DelveInsight's Chronic Refractory Cough pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Chronic Refractory Cough treatment.
* The leading Chronic Refractory Cough Companies such as GSK, Trevi Therapeutics , and others.
* Promising Chronic Refractory Cough Therapies such as GDC-6599, ME-015 (Suplatast Tosilate), HS-10383, NOC-110, BLU-5937, Nalbuphine ER, and others.

Stay ahead with the most recent pipeline outlook for Chronic Refractory Cough. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Refractory Cough Treatment Drugs [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Refractory Cough Emerging Drugs Profile

* GSK5464714: GSK

Camlipixant, also known as BLU-5937 or GSK-5464714, is an orally available small molecule developed by BELLUS Health, a subsidiary of GSK. It is a P2X3 receptor antagonist targeting chronic cough and other related disorders. In a phase 2b parallel group study, patients with =25 coughs per hour who received 50 mg or 200 mg of camlipixant twice daily had a 34% greater reduction in 24-hour cough frequency compared to placebo. Approximately 5% of patients on any of the three camlipixant doses experienced dysgeusia (taste disturbance), which is lower than other P2X3 antagonists. GSK recently acquired BELLUS Health, the company developing camlipixant, for $2 billion. GSK cited camlipixant's potential to be a best-in-class treatment for RCC with significant sales potential. Camlipixant is currently in Phase III stage of clinical trial evaluation for the treatment of Chronic Refractory Cough.

Explore groundbreaking therapies and clinical trials in the Chronic Refractory Cough Pipeline. Access DelveInsight's detailed report now! @ New Chronic Refractory Cough Drugs [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Chronic Refractory Cough Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Chronic Refractory Cough Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Refractory Cough Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chronic Refractory Cough Pipeline Report

* Coverage- Global
* Chronic Refractory Cough Companies- GSK, Trevi Therapeutics, and others.
* Chronic Refractory Cough Therapies- GDC-6599, ME-015 (Suplatast Tosilate), HS-10383, NOC-110, BLU-5937, Nalbuphine ER, and others.
* Chronic Refractory Cough Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Refractory Cough Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chronic Refractory Cough Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Refractory Cough Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Chronic Refractory Cough: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Refractory Cough- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* GSK5464714: GSK
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Chronic Refractory Cough Key Companies
* Chronic Refractory Cough Key Products
* Chronic Refractory Cough- Unmet Needs
* Chronic Refractory Cough- Market Drivers and Barriers
* Chronic Refractory Cough- Future Perspectives and Conclusion
* Chronic Refractory Cough Analyst Views
* Chronic Refractory Cough Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-refractory-cough-pipeline-2024-gsk-trevi-therapeutics]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.